Deutsche Bank Cuts Axsome Therapeutics Price Target to $245, Keeps Buy Rating
Deutsche Bank lowered its price target on Axsome Therapeutics to $245 from $267 and maintained its Buy rating.
Related stories
Revvity Shares Rise 11.4% After Q3 Revenue Beat, Guidance Raise
Revvity shares hit their highest level since April 2022 after the company reported a third-quarter revenue beat and raised full-year guidance.
M impact | EQUITY | Nov 03, 2026, 02:37 PM UTC
Keurig Dr Pepper Shares Fall About 4% on Slower Coffee Growth
The company flagged slower-than-expected growth in its US coffee segment for Q4.
M impact | EQUITY | Nov 03, 2026, 02:37 PM UTC
Volaris Shares Rise 10% at the Open
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Upwork raises annual adjusted profit forecast; shares rise 2.7%
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Proto Labs Raises Multi Jet Fusion 3D Printing Capacity by 50%
Proto Labs said it raised its HP Multi Jet Fusion 3D-printing capacity by 50%.
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC
Volaris shares surge 10% after opening
M impact | EQUITY | Nov 03, 2026, 02:36 PM UTC